GOG-3086 / STRO-002-GM3
Trial Overview
Official Title
A Phase 2 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor alpha (FOLR1)
Study Purpose
To investigate the efficacy and safety of luveltamab tazevibulin in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1.
Diagnosis
High-grade serous ovarian, primary peritoneal, or fallopian tube cancer.Eligibility
Platinum resistant recurrent/persistent. 1-3 prior lines of therapy. FOLR1>25%.
Intervention
Luveltamab tazevibulin IV every 3 weeks testing 2 different dose levels.
For more information, click the link below:
https://clinicaltrials.gov/study/NCT05870748?term=STRO-002-GM3&rank=1
Key Participation Requirements
Trial Location(s)
Gender
Female
Age
18 and Older
Enrollment Status
Recruiting
Phase
Phase II
Methodist Health System Trial Code
GOG-3086